Jacobson Mark L.
SEC CIK 1805812 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | COO | 10.0K | — | $28.81M | 20 | 2024-04-01 | 2026-09-03 |
Most active insiders at AXSM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | TABUTEAU HERRIOT | CEO, Dir, 10% | — | $103.22M |
| 2 | Pizzie Nick | CFO | — | $10.18M |
| 3 | Jacobson Mark L. | COO | — | $8.90M |
| 4 | Coleman Mark | Dir | — | $8.21M |
| 5 | Saad Mark E | Dir | — | $6.21M |
| 6 | Maizel Ari | Chief Commercial Off | — | $2.75M |
| 7 | Mahony Susan | Dir | — | $145.0K |
| 8 | JEFFS ROGER | Dir | — | $141.7K |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-03 19:09 | 2026-09-03 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $12.95 | +10.0K | 10.0K | New | +$129.5K |
| DT | 2026-09-03 19:09 | 2026-09-03 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $208.65 | -10.0K | 0 | -100% | -$2.09M |
| DMT | 2026-05-05 20:34 | 2026-05-04+ | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $12.95 | +4,750 | 233 | New | +$61.5K |
| DMT | 2026-05-05 20:34 | 2026-05-04+ | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $227.95 | -4,750 | 0 | -100% | -$1.08M |
| DT | 2026-02-27 | 2026-02-26 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $2.85 | +35.4K | 35.4K | New | +$100.8K |
| DT | 2026-02-27 | 2026-02-26 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $161.88 | -35.4K | 0 | -100% | -$5.73M |
| DT | 2025-09-22 | 2025-09-22 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $115.96 | -10.0K | 0 | -100% | -$1.16M |
| DT | 2025-09-22 | 2025-09-22 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $2.85 | +10.0K | 10.0K | New | +$28.5K |
| DMT | 2025-09-17 | 2025-09-16 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $114.48 | -45.8K | 0 | -100% | -$5.24M |
| DMT | 2025-09-17 | 2025-09-16 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $4.91 | +40.0K | 40.0K | New | +$196.5K |
| DT | 2025-06-10 | 2025-06-09 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $8.02 | +25.0K | 30.8K | +432% | +$200.5K |
| DT | 2025-06-10 | 2025-06-09 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $110.44 | -25.0K | 5,783 | -81% | -$2.76M |
| DMT | 2025-05-28 | 2025-05-27+ | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $104.07 | -40.7K | 5,783 | -88% | -$4.23M |
| DMT | 2025-05-28 | 2025-05-27+ | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $6.47 | +40.7K | 26.5K | New | +$263.2K |
| DT | 2024-08-09 | 2024-08-09 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $4.04 | +47.7K | 53.5K | +826% | +$192.9K |
| DT | 2024-08-09 | 2024-08-09 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $84.26 | -47.7K | 5,783 | -89% | -$4.02M |
| D | 2024-05-29 | 2024-05-29 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $1.30 | +13.7K | 13.7K | New | +$17.8K |
| D | 2024-05-29 | 2024-05-29 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $74.31 | -7,910 | 5,783 | -58% | -$587.8K |
| DT | 2024-04-01 | 2024-04-01 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | M - OptEx | $1.30 | +24.7K | 24.7K | New | +$32.1K |
| DT | 2024-04-01 | 2024-04-01 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $77.24 | -24.7K | 0 | -100% | -$1.90M |
Purchase Sale Sale after option exercise All abbreviations